Errors in Figure 2 and Table 3

No authors listed

Published Erratum

No authors listed. JAMA Dermatol. 2022.

. 2022 Oct 1;158(10):1221.

doi: 10.1001/jamadermatol.2022.3698.

No abstract available

Erratum for

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS, Seyger MMB, Magariños GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, Somani N, Garrelts A, Papp KA; IXORA-PEDS Investigators. Paller AS, et al. JAMA Dermatol. 2022 May 1;158(5):533-541. doi: 10.1001/jamadermatol.2022.0655. JAMA Dermatol. 2022. PMID: 35416908 Free PMC article. Clinical Trial.

1. Paller AS, Seyger MMB, Magariños GA, et al. . Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. 2022;158(5):533-541. doi:10.1001/jamadermatol.2022.0655 - DOI - PMC - PubMed